Polyganics

21 articles about Polyganics

• Collagen Matrix Acquires Polyganics

  10/5/2022

  Collagen Matrix, Inc., a global leader in regenerative medicine and a Linden Capital Partners portfolio company, announced the acquisition of Polyganics, B.V. Polyganics is a medical technology company that develops and manufactures bioresorbable medical devices.

• First Patient Treated in Polyganics’ ENCASE II Trial for Innovative Dura Sealant Patch, LIQOSEAL®

  5/21/2021

  Randomized controlled trial in the US and Europe will enable LIQOSEAL® to be submitted for FDA approval

• 

  BioSpace Global Roundup, Sept. 17

  9/17/2020

  Companies from across the globe provide updates on their businesses and pipelines.
• 

  BioSpace Global Roundup, May 14

  5/14/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipeline and business.
• 

  BioSpace Global Roundup, Jan. 9

  1/9/2020

  Pharma and biotech companies from across the globe provide business and pipeline updates.

• Polyganics Achieves CE Mark Certification for LIQOSEAL®

  1/7/2020

  Polyganics announced that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect.

• Polyganics Achieves Positive 3-month Follow-up Data of ENCASE I, the First Clinical Trial for LIQOSEAL®

  9/17/2019

  Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has announced positive data from its ENCASE I* clinical trial.

• Polyganics Builds New Facility to Continue Growth, Supported by RIG Subsidy of €3.8 Million

  4/10/2019

  Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth.

• Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure

  10/22/2018

  Polyganics today announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL®, its dura sealant patch. The self-adhesive patch has been developed to reduce cerebrospinal fluid (CSF) leakage following brain surgery.

• Polyganics Strengthens Global Distribution Network with Appointment of Synovis MCA as US-wide Distributor of NEUROCAP®

  9/10/2018

  Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.

• FDA Grants Breakthrough Device Designation to Polyganics’ Liver and Pancreas Sealant Patch

  3/8/2018

  Polyganics announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch.

• Polyganics Awarded €1.2 Million to Complete Clinical Development of Dura Sealant Patch

  12/1/2017

  The grant, together with contributions from the city and province of Groningen, totals EUR 1.2 million.

• Polyganics Announces Enrollment Of The First Patient In Its PROTECT NEURO Study

  4/20/2017

• Polyganics’ "STOP NEUROMA" Study Interim Data Shows Reduction in Pain

  2/16/2017

• Polyganics Announces Birmingham Hand Centre Efficacy Study Of Nerve Conduit Neurolac In Finger Surgery

  12/7/2016

• Polyganics Announces CE Mark For NEUROCAP, The Nerve Capping Device For Treatment And Prevention Of Symptomatic Neuroma

  6/21/2016

• Polyganics Announces Enrollment Of First Patients In Multicenter Study For NEUROCAP Nerve Capping Device

  5/9/2016

• Polyganics Appoints Dr Jan Öhrström To Supervisory Board

  3/15/2016

• Polyganics Receives FDA 510(k) Clearance For Nerve Capping Device NEUROCAP

  1/26/2016

• Polyganics And MicroAire Surgical Instruments Sign Exclusive Distribution Agreement For Peripheral Nerve Repair Portfolio In The US, Canada And Puerto Rico

  1/21/2016